JP2024522200A - トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー - Google Patents

トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー Download PDF

Info

Publication number
JP2024522200A
JP2024522200A JP2023576067A JP2023576067A JP2024522200A JP 2024522200 A JP2024522200 A JP 2024522200A JP 2023576067 A JP2023576067 A JP 2023576067A JP 2023576067 A JP2023576067 A JP 2023576067A JP 2024522200 A JP2024522200 A JP 2024522200A
Authority
JP
Japan
Prior art keywords
derivatives
glu
fapi
acid
equiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522200A5 (enExample
Inventor
フランク、レシュ
マルセル、マーティン
ティルマン、グルース
ウイソン、ムン
チャンドラ、セカール、バル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medianezia GmbH
Original Assignee
Medianezia GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medianezia GmbH filed Critical Medianezia GmbH
Publication of JP2024522200A publication Critical patent/JP2024522200A/ja
Publication of JP2024522200A5 publication Critical patent/JP2024522200A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paints Or Removers (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
  • Medicinal Preparation (AREA)
JP2023576067A 2021-06-08 2022-06-07 トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー Pending JP2024522200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102021114711.5A DE102021114711B4 (de) 2021-06-08 2021-06-08 Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
DE102021114711.5 2021-06-08
PCT/EP2022/065440 WO2022258637A1 (de) 2021-06-08 2022-06-07 Trislinker-konjugierte dimere markierungsvorläufer und daraus abgeleitete radiotracer

Publications (2)

Publication Number Publication Date
JP2024522200A true JP2024522200A (ja) 2024-06-11
JP2024522200A5 JP2024522200A5 (enExample) 2025-01-20

Family

ID=82258261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576067A Pending JP2024522200A (ja) 2021-06-08 2022-06-07 トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー

Country Status (10)

Country Link
US (1) US20250235566A1 (enExample)
EP (1) EP4351663A1 (enExample)
JP (1) JP2024522200A (enExample)
KR (1) KR20240019301A (enExample)
CN (1) CN117642190A (enExample)
AU (1) AU2022288744A1 (enExample)
BR (1) BR112023023149A2 (enExample)
CA (1) CA3222226A1 (enExample)
DE (1) DE102021114711B4 (enExample)
WO (1) WO2022258637A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3248367A1 (en) * 2022-01-14 2023-07-20 Provincial Health Services Authority Radiolabeled compounds for imaging fibroblast-activating protein (FAP) and treating FAP-related disorders
WO2023222558A1 (en) 2022-05-14 2023-11-23 Zounek Alexis Nikolai Precursor and theranostic radiotracer with improved tumor retention
DE102022116009A1 (de) * 2022-06-28 2023-12-28 Positron Precision GmbH Fibroblasten-Aktivierungsprotein adressierender Präkursor und Radiotracer
CN115947775B (zh) * 2023-03-13 2023-06-09 北京先通国际医药科技股份有限公司 一种制备化合物（i）的方法和化合物（i）及其用途
CN117304125A (zh) * 2023-09-12 2023-12-29 北京师范大学 靶向PSMA的EuK二聚体化合物及其药用盐和应用
WO2025063849A2 (en) * 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025087229A1 (zh) * 2023-10-27 2025-05-01 四川科伦博泰生物医药股份有限公司 一类喹啉结构的配体化合物及其放射性或非放射性标记物以及应用
WO2025125335A1 (en) 2023-12-13 2025-06-19 Radiovaxx Gmbh Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group
CN120136958A (zh) * 2023-12-13 2025-06-13 无锡诺宇医药科技有限公司 Fap靶向放射性药物
WO2025125621A1 (en) 2023-12-14 2025-06-19 Radiovaxx Gmbh Cancer-associated protein-targeted strong or covalently binding precursor compounds and radiotracers
WO2025146433A1 (en) 2024-01-05 2025-07-10 Radiovaxx Gmbh Precursor and theranostic radiotracer with prolonged tumor retention
TW202535358A (zh) * 2024-01-11 2025-09-16 大陸商上海復星醫藥產業發展有限公司 一種ｆａｐ結合化合物、金屬錯合物及其用途
CN118271393B (zh) * 2024-05-31 2024-09-03 中国药科大学 一种靶向fap的二聚化合物及其探针和应用
EP4696686A1 (en) * 2024-08-15 2026-02-18 Tetrakit Technologies ApS Fapi theranostic compounds assembled with tetrazine ligation
CN119060093B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN119060094B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN118955353A (zh) * 2024-10-14 2024-11-15 南京恒远科技开发有限公司 一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法
CN119679977B (zh) * 2024-12-16 2025-09-05 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种Al18F示踪剂一体化冻干粉的制备方法、试剂盒及其应用
CN119409613B (zh) * 2025-01-03 2025-04-11 南京恒远科技开发有限公司 (s)-[2-(2-氰基-4,4-二氟吡咯烷-1-基)-2-氧代-乙基]氨基甲酸叔丁酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
US11167048B2 (en) * 2018-12-14 2021-11-09 The Curators Of The University Of Missouri Dual targeting ligand for cancer diagnosis and treatment
CN114502528B (zh) * 2019-09-20 2024-09-06 墨尔本大学 成像和治疗组合物
DE102021101216A1 (de) * 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CN113880810B (zh) * 2021-09-24 2023-02-28 厦门大学 一种核素标记的配合物及其制备方法和应用

Also Published As

Publication number Publication date
CA3222226A1 (en) 2022-12-15
DE102021114711A1 (de) 2022-12-08
WO2022258637A1 (de) 2022-12-15
CN117642190A (zh) 2024-03-01
AU2022288744A9 (en) 2023-12-21
DE102021114711B4 (de) 2023-11-02
AU2022288744A1 (en) 2023-12-14
KR20240019301A (ko) 2024-02-14
BR112023023149A2 (pt) 2024-01-23
EP4351663A1 (de) 2024-04-17
US20250235566A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
JP2024522200A (ja) トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー
JP7653082B2 (ja) スクアリン酸カップリングを有する標識前駆体
US6005083A (en) Bridged aromatic substituted amine ligands with donor atoms
US20240100201A1 (en) Labeling precursors and radiotracers for nuclear medicine diagnosis and therapy of prostate cancer-induced bone metastases
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
JP2025138647A (ja) 核医学細胞傷害性デュアルセラノスティクスのためのスマートドラッグデリバリーシステムおよび医薬キット
JP2025507966A (ja) 核医学において用いられるセラノスティクスのための３つ以上の標的ベクターを有する標識前駆体および放射性トレーサー
JP2025500410A (ja) 癌の治療および診断のためのｆａｐ標的医薬
HK40100289A (zh) 缀合有三接头的二聚体标记前体和由其衍生的放射性示踪剂
HK40077105B (zh) 具有方酸连接的标记前体
HK40077105A (en) Marking precursor with squaric acid coupling
JP2025540658A (ja) 神経ペプチドｙ１受容体（ｎｐｙ１ｒ）を標的とした治療薬およびその使用
HK40092509A (zh) 用於核医学诊断和治疗前列腺癌诱发的骨转移瘤的标记前体和放射性示踪剂
CN120590466A (zh) 一种靶向成纤维细胞活化蛋白的化合物及其应用
HK40113686A (zh) 用於核医学治疗诊断的具有三个或更多个靶向载体的标志物前体和放射性示踪剂
HK40054156A (en) Marking precursor with squaric acid coupling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406